MCID: MYL005
MIFTS: 72

Myelofibrosis malady

Genetic diseases, Rare diseases, Cancer diseases, Bone diseases, Immune diseases categories
Download this MalaCard

Summaries for Myelofibrosis

About this section
Sources:
8Disease Ontology, 21Genetics Home Reference, 43NIH Rare Diseases, 65Wikipedia, 47OMIM, 33MalaCards
See all sources

Fully expand this MalaCard
NIH Rare Diseases:43 Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. although myelofibrosis can occur at any age, it typically develops after the age of 50. in most cases, myelofibrosis gets progressively worse. treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    last updated: 8/17/2011

MalaCards: Myelofibrosis, also known as primary myelofibrosis, is related to polycythemia and polycythemia vera. An important gene associated with Myelofibrosis is JAK2 (Janus kinase 2), and among its related pathways are Integrin alphaIIb beta3 signaling and Paxillin-dependent events mediated by a4b1. The drug busulfan and the compounds megapoietin and pp 100 have been mentioned in the context of this disorder. Affiliated tissues include the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue, bone and bone marrow, and related mouse phenotypes are tumorigenesis and embryogenesis.

Disease Ontology:8 A myeloma that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

Genetics Home Reference:21 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.

Wikipedia:65 Myelofibrosis, also known as osteomyelofibrosis, is a disorder of the bone marrow. It is currently... more...

Description from OMIM:47 254450

Aliases & Classifications for Myelofibrosis

About this section
Sources:
8Disease Ontology, 43NIH Rare Diseases, 22GTR, 10DISEASES, 45Novoseek, 31LifeMap Discovery™, 62UMLS, 21Genetics Home Reference, 35MeSH, 47OMIM, 58SNOMED-CT, 40NCIt, 27ICD9CM
See all sources

Classifications:



Aliases & Descriptions:

myelofibrosis 8 43 22 10 45 31 62
primary myelofibrosis 8 43 21 45 62
agnogenic myeloid metaplasia 8 43 21 45
myeloid metaplasia 43 21 45 62
idiopathic myelofibrosis 43 21 45
chronic idiopathic myelofibrosis 8 21
megakaryocytic myelosclerosis 8 62
myelofibrosis with myeloid metaplasia 21
idiopathic bone marrow fibrosis 8
bone marrow fibrosis 8
myelosclerosis, nos 8
aleukemic myelosis 8
myelosclerosis 8


External Ids:

Disease Ontology8 DOID:4971
MeSH35 D055728
OMIM47 254450
NCIt40 C2862
ICD9CM27 238.76

Related Diseases for Myelofibrosis

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Myelofibrosis family:

Familial Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 206)
idRelated DiseaseScoreTop Affiliating Genes
1polycythemia31.0CD177, IL3, JAK2, EPO, MPL, THPO
2polycythemia vera30.8CD177, KIT, IL3, JAK2, EPO, MPL
3leukemia30.8THPO, MPL, EPO, JAK2, IL3, KIT
4splenomegaly30.7THPO, MPL, EPO, JAK2
5leukemoid reaction30.6IL3, GATA1
6myeloid leukemia30.4THPO, MPL, JAK2, IL3, KIT, GATA1
7megakaryocytic leukemia30.4THPO, IL3, GATA1
8myelodysplastic syndromes30.3THPO, MPL, CD177, GATA1, KIT, IL3
9chronic myelomonocytic leukemia30.3MPL, JAK2, KIT
10sarcoma30.3KIT, JAK2, THPO
11thrombocytosis30.3THPO, MPL, EPO, JAK2, IL3, CD177
12pancytopenia30.3THPO, MPL, EPO, IL3
13thrombocytopenia30.3THPO, MPL, EPO, IL3, GATA1
14hypereosinophilic syndrome30.3IL3, KIT
15chronic myeloproliferative disease30.2JAK2, MPL, THPO
16beta thalassemia30.2EPO, GATA1
17myeloma30.2EPO, JAK2, IL3, FGF2
18hypersplenism30.1THPO
19myelofibrosis, somatic30.1SH2B3, JAK2
20systemic mastocytosis30.1JAK2, KIT
21myeloproliferative disorder30.0FGF2, CD177, GATA1, KIT, IL3, JAK2
22refractory anemia29.9KIT, IL3, JAK2, EPO, MPL, THPO
23chronic myeloid leukemia29.8MPL, THPO, EPO, JAK2, IL3, CD177
24aplastic anemia29.7THPO, MPL, EPO, IL3, GATA1
25hemorrhagic thrombocythemia29.7KIT, IL3, JAK2, EPO, MPL, THPO
26deficiency anemia29.6THPO, MPL, EPO, JAK2, IL3, GATA1
27erythrocytosis29.6MPL, EPO, JAK2, IL3, CD177
28neutropenia29.6THPO, MPL, EPO, IL3, CD177
29acute lymphocytic leukemia29.6THPO, MPL, JAK2, IL3, KIT, GATA1
30acute leukemia29.6THPO, MPL, EPO, JAK2, IL3, KIT
31essential thrombocythemia10.8
32acute panmyelosis with myelofibrosis10.6
33osteosclerosis10.4
34acute myeloid leukemia10.4
35hypertension10.3
36nocardiosis10.3
37aspergillosis10.3
38hepatic vascular disease10.3
39vascular disease10.3
40hematopoietic stem cell transplantation10.3
41endotheliitis10.2
42pyridoxine deficiency10.2
43rickets10.2
44hepatitis10.2
45myelofibrosis with myeloid metaplasia, somatic10.2
46lymphoblastic leukemia10.1
47multiple myeloma10.1
48familial myelofibrosis10.1
49gray platelet syndrome10.1
50thrombocythemia 110.1THPO

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to myelofibrosis

Symptoms for Myelofibrosis

About this section
Sources:
47OMIM
See all sources


Clinical features from OMIM:

254450

Drugs & Therapeutics for Myelofibrosis

About this section
Sources:
42NIH Clinical Center, 6ClinicalTrials, 31LifeMap Discovery™, 62UMLS, 41NDF-RT
See all sources

Drug clinical trials:

Search ClinicalTrials for Myelofibrosis

Search NIH Clinical Center for Myelofibrosis

Inferred drug relations via UMLS62/NDF-RT41:

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Myelofibrosis

About this section
Sources:
22GTR
See all sources

Genetic tests related to Myelofibrosis:

id Genetic test Affiliating Genes
1 Myelofibrosis22

Anatomical Context for Myelofibrosis

About this section
Sources:
33MalaCards, 14FMA
See all sources

MalaCards organs/tissues related to Myelofibrosis:

33
Bone, Bone marrow, Myeloid, Spleen, Liver, T cells, Endothelial, Monocytes, Nk cells, B cells, Prostate, Lung, Whole blood, Colon, Breast, Lymph node, Brain, Spinal cord, Testes, Kidney, Ovary

FMA organs/tissues related to Myelofibrosis:

14
The bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue

Animal Models for Myelofibrosis or affiliated genes

About this section
Sources:
37MGI
See all sources

MGI Mouse Phenotypes related to Myelofibrosis:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.6FGF2, KIT, IL3, JAK2
2MP:00053808.6MPL, EPO, JAK2, KIT, GATA1
3MP:00028738.1EPO, JAK2, FKBP5, KIT, GATA1
4MP:00053877.6THPO, SH2B3, MPL, JAK2, IL3, KIT
5MP:00053847.3SH2B3, MPL, EPO, JAK2, IL3, KIT
6MP:00053767.2MPL, EPO, JAK2, FKBP5, IL3, KIT
7MP:00107687.1MPL, EPO, JAK2, FKBP5, IL3, KIT
8MP:00053977.0FGF2, THPO, SH2B3, MPL, EPO, JAK2

Publications for Myelofibrosis

About this section
Sources:
52PubMed
See all sources

Articles related to Myelofibrosis:

(show top 50)    (show all 783)
idTitleAuthorsYear
1
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. (23558523)
2013
2
Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. (24176039)
2013
3
Reversible bone marrow aplasia induced by pegylated interferon-I+-2a therapy in a patient with primary myelofibrosis. (24067929)
2013
4
Chromosome 5q deletion is extremely rare in patients with myelofibrosis. (23391517)
2013
5
Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes. (23571153)
2013
6
Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure. (23110685)
2013
7
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. (23349007)
2013
8
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. (23555782)
2013
9
The relationship of the active and latent forms of TGF-I^1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. (22200991)
2012
10
Myelofibrosis: a cause of increased transfusion requirement in a child with I^-thalassemia intermedia. (22009011)
2012
11
Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults. (22389089)
2012
12
Guideline for the diagnosis and management of myelofibrosis. (22651893)
2012
13
JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis. (23359764)
2012
14
GR SNP helps transform myelofibrosis. (23065009)
2012
15
Ruxolitinib for myelofibrosis therapy: current context, pros and cons. (22285996)
2012
16
Ruxolitinib: in the treatment of myelofibrosis. (23061804)
2012
17
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. (21480207)
2011
18
Ruxolitinib for the treatment of myelofibrosis. (22146225)
2011
19
Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth? (21296418)
2011
20
The surgical palliative treatment of myelofibrosis. Personal experience. (21682106)
2011
21
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. (19786111)
2010
22
Pyoderma gangrenosum associated with chronic idiopathic myelofibrosis after coronary artery bypass graft surgery. (19846444)
2010
23
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. (20113333)
2010
24
Thrombosis in primary myelofibrosis: incidence and risk factors. (19965680)
2010
25
JAK inhibition in myelofibrosis. (21158663)
2010
26
Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. (19052692)
2009
27
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. (19720904)
2009
28
Massive eyelid thickening in pachydermoperiostosis with myelofibrosis. (19617796)
2009
29
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. (19616600)
2009
30
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. (18266209)
2008
31
Plasma cell leukemia with myelofibrosis. (19039200)
2008
32
Myelofibrosis in a child with EBV-associated hemophagocytic lymphohistiocytosis. (18454467)
2008
33
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. (17361221)
2007
34
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (17317589)
2007
35
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. (17162218)
2006
36
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. (16834459)
2006
37
Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. (15755503)
2005
38
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer. (15942101)
2005
39
Acute panmyelosis with myelofibrosis: clinical, immunophenotypic and cytogenetic study of twelve cases. (15223649)
2004
40
Systemic lupus erythematosus presenting with pancytopenia due to bone marrow myelofibrosis in a 22-year-old male. (16163223)
2004
41
Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. (12706407)
2003
42
SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. (12888313)
2003
43
Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. (12788793)
2003
44
The therapy of myelofibrosis: targeting pathogenesis. (12430941)
2002
45
Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis. (11330433)
2001
46
Erythroleukemia following erythropoietin therapy, extramedullary hematopoiesis, and splenectomy in a patient with myelofibrosis and myeloid metaplasia. (11391725)
2001
47
Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. (10550553)
1999
48
Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. (10804000)
1999
49
PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis. (10497847)
1999
50
Myelofibrosis secondary to renal osteodystrophy. (8730443)
1996

Variations for Myelofibrosis

About this section

Expression for genes affiliated with Myelofibrosis

About this section
Sources:
2BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Pathways for genes affiliated with Myelofibrosis

About this section
Sources:
50PathCards, 55Reactome, 38NCBI BioSystems Database, 5Cell Signaling Technology, 60Thomson Reuters, 54R&D Systems, 53QIAGEN, 30KEGG
See all sources

Pathways related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 32)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9MPL, THPO
2
Show member pathways
Paxillin-independent events mediated by a4b1 and a4b738
a4b1 and a4b7 Integrin signaling38
9.8JAK2, EPO
39.8JAK2, GATA1
4
Show member pathways
Development Thrombopoetin signaling via JAK STAT pathway60
9.6JAK2, MPL, THPO
5
Show member pathways
IL-9 Signaling Pathway38
Development Thrombopoietin regulated cell processes60
IL-7 Signaling Pathway38
Immune response IL 9 signaling pathway60
9.6THPO, MPL, JAK2
69.5FGF2, KIT
7
Show member pathways
EPO Receptor Signaling38
EPO signaling pathway38
9.4JAK2, EPO, SH2B3
8
Show member pathways
9.4FGF2, JAK2, MPL
99.4GATA1, JAK2, SH2B3
10
Show member pathways
Development EDNRB signaling60
Development ACM2 and ACM4 activation of ERK60
Cell adhesion Integrin inside out signaling60
Development G Proteins mediated regulation MARK ERK signaling60
Signal transduction IP3 signaling60
Development Angiotensin signaling via PYK260
Development EPO induced MAPK pathway60
9.3EPO, JAK2, KIT
119.2JAK2, KIT, FGF2
129.2GATA1, IL3, JAK2
13
Show member pathways
9.1FGF2, IL3, THPO
149.0GATA1, KIT, IL3
15
Show member pathways
Type III interferon signaling38
8.9MPL, EPO, JAK2, IL3
16
Show member pathways
Signaling events mediated by Stem cell factor receptor (c-Kit)38
8.9SH2B3, EPO, JAK2, KIT
17
Show member pathways
8.8SH2B3, JAK2, KIT, FGF2
188.7KIT, IL3, EPO, THPO
19
Show member pathways
8.6FGF2, KIT, IL3, THPO
20
Show member pathways
8.6FGF2, KIT, IL3, THPO
21
Show member pathways
8.6THPO, IL3, KIT, FGF2
22
Show member pathways
8.6THPO, IL3, KIT, FGF2
23
Show member pathways
8.6THPO, IL3, KIT, FGF2
24
Show member pathways
8.4MPL, EPO, JAK2, IL3, KIT
25
Show member pathways
8.3FGF2, KIT, IL3, JAK2, THPO
26
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
27
Show member pathways
8.3KIT, IL3, JAK2, THPO, FGF2
28
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
29
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
308.2EPO, JAK2, IL3, KIT, FGF2
31
Show member pathways
8.0THPO, SH2B3, MPL, JAK2, GATA1, CD177
32
Show member pathways
7.6FGF2, THPO, MPL, EPO, JAK2, IL3

Compounds for genes affiliated with Myelofibrosis

About this section
Sources:
45Novoseek, 24HMDB, 11DrugBank, 29IUPHAR, 51PharmGKB, 61Tocris Bioscience, 3BitterDB
See all sources

Compounds related to Myelofibrosis according to GeneCards/GeneDecks:

(show top 50)    (show all 81)
idCompoundScoreTop Affiliating Genes
1megapoietin4510.2THPO, MPL
2pp 1004510.1JAK2, EPO
3beta-tyrosine4510.0JAK2, KIT
4thromboxane45 2410.8THPO, MPL, GATA1
5pegfilgrastim45 1110.8EPO, IL3
6su6668459.8KIT, FGF2
7il 11459.7IL3, EPO
8anagrelide45 1110.7JAK2, EPO, MPL, THPO
9pixy321459.6THPO, EPO, IL3
10mafosfamide459.6THPO, IL3
11amifostine45 1110.6IL3, EPO, THPO
12filgrastim45 1110.6IL3, EPO, THPO
13gm-csf45 2910.6IL3, EPO, THPO
14aclarubicin459.5GATA1, IL3
15carboplatin45 51 1111.4THPO, EPO, IL3
16doxycycline45 1110.4FGF2, IL3, EPO
17iron45 2410.3THPO, MPL, EPO, GATA1
185-aza-2deoxycytidine459.3THPO, EPO, JAK2, IL3
19gf 109203x45 6110.1FGF2, JAK2, THPO
20ascorbic acid45 2410.1EPO, JAK2, IL3, FGF2
215fluorouracil459.1KIT, IL3, MPL, THPO
22genistein45 29 61 3 24 1114.0THPO, JAK2, IL3, FGF2
23phosphotyrosine459.0KIT, IL3, JAK2, SH2B3
24butyrate458.9THPO, EPO, JAK2, IL3, GATA1
25agar458.9FGF2, IL3, JAK2, MPL, THPO
26vincristine45 51 1110.9FGF2, KIT, IL3
27paclitaxel45 51 1110.9THPO, IL3, KIT, FGF2
28ly294002458.8THPO, EPO, JAK2, IL3, FGF2
29imatinib45 51 1110.8THPO, EPO, JAK2, IL3, KIT
30steroid458.8THPO, JAK2, FKBP5, KIT, GATA1
31alanine458.8FGF2, IL3, JAK2, MPL, THPO
32cytarabine45 51 1110.7THPO, EPO, IL3, KIT, GATA1
33pd 98,059458.7THPO, JAK2, IL3, KIT, FGF2
34methylcellulose458.7THPO, EPO, IL3, KIT, FGF2
35cyclosporin a45 29 6110.6EPO, JAK2, FKBP5, IL3, FGF2
36dexamethasone45 51 29 1111.6FGF2, IL3, FKBP5, JAK2, THPO
37lactate458.6THPO, EPO, IL3, KIT
38cysteine458.5KIT, IL3, JAK2, MPL, THPO
39gp 130458.5THPO, MPL, EPO, JAK2, IL3, KIT
40hydroxyurea45 51 1110.5GATA1, KIT, IL3, JAK2, EPO, THPO
41thymidine45 249.4THPO, EPO, JAK2, IL3, KIT, FGF2
42actinomycin d458.3THPO, JAK2, IL3, KIT, GATA1, FGF2
43vegf458.3THPO, MPL, EPO, JAK2, KIT, GATA1
44rapamycin458.3THPO, EPO, JAK2, FKBP5, IL3, KIT
45estrogen458.3THPO, JAK2, IL3, KIT, GATA1, FGF2
46retinoic acid45 249.3THPO, JAK2, IL3, KIT, GATA1, FGF2
47serine458.2MPL, JAK2, IL3, KIT, GATA1, FGF2
48cycloheximide458.1JAK2, FKBP5, IL3, KIT, GATA1, FGF2
49phosphatidylinositol457.7THPO, SH2B3, MPL, EPO, JAK2, IL3
50tyrosine456.8THPO, SH2B3, MPL, EPO, JAK2, IL3

GO Terms for genes affiliated with Myelofibrosis

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:0056158.2FGF2, KIT, IL3, EPO, THPO

Biological processes related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1response to axon injuryGO:0486789.9EPO, FGF2
2positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.8KIT, JAK2
3cellular response to thyroid hormone stimulusGO:0970679.8GATA1, KIT
4positive regulation of phospholipase C activityGO:0108639.7FGF2, KIT
5positive regulation of phosphatidylinositol 3-kinase activityGO:0435529.6FGF2, KIT
6positive regulation of DNA replicationGO:0457409.6EPO, IL3
7positive regulation of phosphatidylinositol 3-kinase signalingGO:0140689.6JAK2, KIT
8erythrocyte differentiationGO:0302189.6GATA1, KIT, JAK2
9activation of MAPKK activityGO:0001869.4FGF2, JAK2
10positive regulation of peptidyl-tyrosine phosphorylationGO:0507319.4JAK2, IL3, GATA1
11negative regulation of cell proliferationGO:0082859.4FGF2, GATA1, JAK2
12positive regulation of tyrosine phosphorylation of Stat5 proteinGO:0425239.0KIT, IL3, JAK2, EPO
13signal transductionGO:0071658.9FGF2, KIT, JAK2, EPO
14embryonic hemopoiesisGO:0351628.8SH2B3, IL3, KIT, GATA1
15positive regulation of cell proliferationGO:0082848.5EPO, JAK2, IL3, KIT, FGF2
16blood coagulationGO:0075968.2THPO, SH2B3, MPL, JAK2, GATA1, CD177

Molecular functions related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1cytokine activityGO:0051259.1FGF2, IL3, THPO
2growth factor activityGO:0080838.8FGF2, IL3, THPO

Products for genes affiliated with Myelofibrosis

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Myelofibrosis

About this section
4CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
52PubMed
53QIAGEN
59SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet